Biogen Sees Unusually Large Options Volume (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the target of some unusual options trading activity on Tuesday. Traders acquired 6,120 put options on the stock. This is an increase of approximately 232% compared to the typical volume of 1,846 put options.

Analyst Ratings Changes

BIIB has been the subject of several research analyst reports. Zacks Research upgraded shares of Biogen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Barclays lifted their price target on shares of Biogen from $200.00 to $230.00 and gave the company an “equal weight” rating in a report on Wednesday, October 28th. Wells Fargo & Company upped their target price on shares of Biogen from $250.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, October 20th. Bank of America lifted their price objective on shares of Biogen from $219.00 to $244.00 and gave the stock a “neutral” rating in a report on Thursday, October 22nd. Finally, Mizuho boosted their price target on Biogen from $221.00 to $241.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $254.41.

Get Our Latest Stock Report on BIIB

Institutional Investors Weigh In On Biogen

Large investors have recently modified their holdings of the stock. Probity Advisors Inc. increased its position in shares of Biogen by 3.6% during the third quarter. Probity Advisors Inc. now owns 1,183 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 41 shares in the last quarter. Forum Financial Management LP lifted its position in Biogen by 2.4% in the third quarter. Forum Financial Management LP now owns 1,936 shares of the biotechnology company’s stock worth $437,000 after buying an additional 46 shares during the last quarter. Integrated Advisors Network LLC lifted its stake in shares of Biogen by 3.5% during the 3rd quarter. Integrated Advisors Network LLC now owns 1,403 shares of the biotechnology company’s stock worth $317,000 after acquiring an additional 48 shares during the last quarter. Wedbush Securities Inc. grew its stake in Biogen by 5.1% in the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 56 shares in the last quarter. Finally, Meeder Advisory Services Inc. lifted its stake in shares of Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after purchasing an additional 57 shares during the period. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

Shares of BIIB stock traded down $1.98 during trading on Tuesday, reaching $249.68. 371,369 shares of the company’s stock were exchanged, compared to its average volume of 1,203,917. The stock has a market capitalization of $36.91 billion, a PE ratio of 106.68, a PEG ratio of 2.84 and a beta of 0.10. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39. Biogen has a twelve month low of $160.36 and a twelve month high of $261.00. The firm’s fifty day moving average price is $233.96 and its 200-day moving average price is $205.42.

Biogen (NASDAQ:BIIB – Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. The firm had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.63 billion. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the firm posted $4.81 earnings per share. As a group, sell-side analysts anticipate that Biogen will post 12.46 EPS for the current year.

Top Biogen Stories

These are some of the BIIB stories that stood out recently:

  • Positive Sentiment: Five-year data for LEQEMBI (lecanemab), developed and commercialized with Eisai, showed sustained benefits for some patients with early Alzheimer’s disease. Compared with external natural-history data, treatment was associated with a 36% lower relative risk of progressing to the next disease stage; among low-tau patients, 62% showed improvement on a cognitive and daily-living measure. No new safety findings emerged, though the results include comparisons with external datasets rather than a concurrent control group at five years. Stronger evidence of durable benefit could support the drug’s commercial prospects. Five-year lecanemab data
  • Positive Sentiment: Wall Street Zen upgraded Biogen, adding a favorable analyst signal, though the report does not provide the rationale or rating details. Wall Street Zen upgrade
  • Negative Sentiment: Traders bought 6,120 BIIB put options, 232% above the average daily volume of 1,846. The activity may reflect hedging or bearish expectations, but options volume alone does not establish a market direction.

About Biogen

(Get Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

Read More

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.